1 / 14

Filgrastim

The Reliable Life Defense. Filgrastim. Filgrastim Composition. Each vial contains: Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume of 1 ml. Pharmacological Action.

reece
Download Presentation

Filgrastim

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Reliable Life Defense Filgrastim

  2. FilgrastimComposition • Each vial contains: • Recombinant human granulocyte colony-stimulating factor (G-CSF) 300 µg in a volume of 1 ml.

  3. Pharmacological Action • Filgrastim is a glycoprotein which acts on hematopoietic cells in bone marrow, stimulating their proliferation & differentiation to neutrophils. • Filgrastimaccelerates improvement of neutrophils count & their functional activation (enhanced phagocytic ability)

  4. Filgrastim Indications • To reduce the incidence, severity & duration of neutropenia associated with chemotherapy (Interferon) • Cancer patients receiving myelosuppressive chemotherapy • Patients with acute myeloid leukemia receiving induction Chemotherapy • Patients with severe chronic neutropenia

  5. Filgrastim Indications • Cancer patients undergoing peripheral Blood Progenitor Cell Collection and Therapy • Cancer patients receiving bone marrow transplant • Patients with acute myeloid leukemia receiving induction Chemotherapy • Patients with severe chronic neutropenia

  6. Clinical Pharmacological Response Filgrastim dose: 4 to 8 mcg/kg for up to 14 consecutive days following each cycle of chemotherapy Cancer Patients Receiving Myelo-suppressive Chemotherapy Duhrsen U‚ Villeval JL‚ Boyd J‚ et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-2081.

  7. Dosage & Administration • Dosage & Administration is individualized according to patient’s clinical course & average neutrophil count • Filgrastim should be given once daily by I.V. or S.C. injection (after 24 – 48 hours of administration of chemotherapy or radiotherapy)

  8. Filgrastim Dosage • Cancer patients receiving myelosuppressive chemotherapy: • 5 µg/kg body weight /day as a single daily dose by S.C. injection or I.V. infusion over 15 – 30 minutes

  9. Filgrastim Dosage • Patients with severe chronic neutropenia: • Initial dose • Congenital: 6µg/kg body weight twice daily by S.C. injection • Idiopathic: 5µg/kg body weight /day as a single S.C. injection

  10. Filgrastim Dosage • Cancer patients receiving bone marrow transplant: • 10 µg/kg body weight /day as I.V. infusion for 4 – 24 hours

  11. Filgrastim Dosage • Cancer patients undergoing peripheral Blood Progenitor Cell Collection and Therapy: • 10 µg/kg body weight /day either as a bolus or a continuous infusion at least 4 days before the first procedure for 6 – 7 days, on day 5,6,7 . • Dosemodification in case of reaching WBCs count exceeding 100,000 / mm3

  12. Filgrastim Storage • Filgrastim is kept in refrigerator at 2 – 8oC • Filgrastim can be kept at room temp. for a maximum of 24 hours • Filgrastimvial should not be shacked • Filgrastim vial should not be reused, the unused portion must be discarded

  13. Filgrastim Pack & Price • 1 vial (1 ml) … 350 L E.

  14. The Reliable Life Defense Filgrastim

More Related